We are a small firm focused in the diagnostics and research tools industry, which is a relatively narrow space to focus in for boutique consulting. On one hand it makes us very specialized and have a strong reputation with clients in this space. On the other hand, there is not as much money to be made, relative to the pharma industry. I think the firm's leadership recognizes that and while in the past there's been no desire to push into pharma work, this is changing, with one of the partners driving the charge. Additionally, the Emmes acquisition recently opens up a lot of opportunity to drive new recurring revenue streams, so overall the outlook is bright.